Isicom

Levodopa, the active ingredient in Isicom, is a dopamine precursor with a peripheral decarboxylase inhibitor presented as an oral tablet for oral use. It is employed to treat Parkinson's disease and Parkinsonian syndrome by compensating for central dopamine deficiency.

GNH USA supplies Isicom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Isicom, containing levodopa and carbidopa, is used in the management of dopamine‑deficiency movement disorders.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates tremor and gait disturbances associated with dopamine loss. - Levodopa‑responsive movement disorders: provides symptomatic relief in conditions that respond to dopamine replacement.

Levodopa/carbidopa therapy may be associated with a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia or vivid dreams - Dry mouth

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or arrhythmia - Neuroleptic malignant syndrome (very rare) - Allergic skin reactions such as rash or urticaria

When prescribing Isicom, clinicians should observe several precautionary measures to optimize safety.

- Dose titration: start with the lowest effective dose and increase gradually. - Blood pressure monitoring: watch for orthostatic hypotension, especially in the elderly. - Psychiatric assessment: monitor for hallucinations, confusion, or mood changes. - Renal/hepatic function: adjust dosing in patients with significant impairment. - Concomitant drugs: avoid concurrent use of non‑selective MAO inhibitors. - Store at below 25°C: keep in the original pack, protect from moisture.

Levodopa/carbidopa can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk hypertensive crisis. - Anticholinergic agents: may mask motor symptom changes. - Serotonergic drugs (e.g., SSRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - Iron or calcium supplements: reduce levodopa absorption. - High‑protein meals: compete for transport across the gut and diminish bioavailability.